Genetic Engineering & Biotechnology News recently published a feature story entitled ‘Immune Cell Therapy May Become More Naturalistic’.

Alloplex Biotherapeutics’ CEO, Dr. Frank Borriello, was interviewed – and quoted extensively – as a featured expert in the story which explores questions about engineering options and cell sources for Immune Cell Therapy. 

The article’s author, Tiffany Yesavage, PhD, writes: “Where cyborgian CAR T cells fall short, naturally occurring immune cells may push through – provided they have been properly recruited and trained.”